James E. Foley - Publications, H-index & Citations

James E. Foley

novartis usa

61H指数

171论文数

1.3W被引数

收录论文 56

发表时间

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2019-11-08

OAAI

Foley, James E.

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes

DIABETIC MEDICINE

IF3.4

2019-02-12

OAAI

Matthews, D. R.; Paldanius, P. M.; Proot, P.; Foley, J. E.; Stumvoll, M.; Del Prato, S.

In Vitro Lipolysis is Associated with Whole-Body Lipid Oxidation and Weight Gain in Humans

OBESITY

IF4.7

2016-11-21

OAAI

Frankl, Joseph; Piaggi, Paolo; Foley, James E.; Krakoff, Jonathan; Votruba, Susanne B.

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

DIABETES

IF7.5

2016-04-05

OAAI

Nauck, Michael A.; Kind, Joachim; Kthe, Lars D.; Holst, Jens J.; Deacon, Carolyn F.; Broschag, Matthias; He, Yan Ling; Kjems, Lise; Foley, James

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

DIABETOLOGIA

IF10.2

2016-02-19

OAAI

Ahren, Bo; Foley, James E.

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

DIABETOLOGIA

IF10.2

2015-06-12

OAAI

Kothny, Wolfgang; Lukashevich, Valentina; Foley, James E.; Rendell, Marc S.; Schweizer, Anja

Effect of Vildagliptin on Hepatic Steatosis

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2015-04-01

107

OAAI

Macauley, Mavin; Hollingsworth, Kieren G.; Smith, Fiona E.; Thelwall, Peter E.; Al-Mrabeh, Ahmad; Schweizer, Anja; Foley, James E.; Taylor, Roy

Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial

DIABETIC MEDICINE

IF3.4

2014-07-17

OAAI

Del Prato, S.; Foley, J. E.; Kothny, W.; Kozlovski, P.; Stumvoll, M.; Paldanius, P. M.; Matthews, D. R.

Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies

DIABETOLOGIA

IF10.2

2014-03-29

OAAI

Ahren, Bo; Mathieu, Chantal; Bader, Giovanni; Schweizer, Anja; Foley, James E.

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2014-03-17

PREAI

Farngren, J.; Persson, M.; Schweizer, A.; Foley, J. E.; Ahren, B.

Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

DIABETOLOGIA

IF10.2

2013-05-02

PREAI

Omar, B. A.; Vikman, J.; Winzell, M. S.; Voss, U.; Ekblad, E.; Foley, J. E.; Ahren, B.

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus 在2型糖尿病患者中，使用或不使用二甲双胍，将维格列汀添加到胰岛素中改善血糖控制

DIABETES OBESITY & METABOLISM

IF5.7

2012-11-01

PREAI

Kothny, W.; Foley, J.; Kozlovski, P.; Shao, Q.; Gallwitz, B.; Lukashevich, V.

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2012-10-01

OAAI

Farngren, Johan; Persson, Margaretha; Schweizer, Anja; Foley, James E.; Ahren, Bo

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man

DIABETES OBESITY & METABOLISM

IF5.7

2012-09-09

PREAI

Busch, S. J.; Hoffmann, P.; Sahota, P.; Johnson, R.; Kothny, W.; Meyer, F.; Foley, J. E.

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

DIABETES OBESITY & METABOLISM

IF5.7

2011-07-26

144

PREAI

Ahren, B.; Schweizer, A.; Dejager, S.; Villhauer, E. B.; Dunning, B. E.; Foley, J. E.

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

DIABETOLOGIA

IF10.2

2011-05-06

OAAI

Foley, J. E.; Bunck, M. C.; Moller-Goede, D. L.; Poelma, M.; Nijpels, G.; Eekhoff, E. M.; Schweizer, A.; Heine, R. J.; Diamant, M.

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2011-04-01

OAAI

Vardarli, Irfan; Nauck, Michael A.; Koethe, Lars D.; Deacon, Carolyn F.; Holst, Jens J.; Schweizer, Anja; Foley, James E.

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

DIABETES OBESITY & METABOLISM

IF5.7

2011-01-24

PREAI

Ahren, B.; Foley, J. E.; Bosi, E.

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trials

DIABETES OBESITY & METABOLISM

IF5.7

2010-11-28

PREAI

Schweizer, A.; Dejager, S.; Foley, J. E.; Shao, Q.; Kothny, W.

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

DIABETES OBESITY & METABOLISM

IF5.7

2010-07-23

179

PREAI

Matthews, D. R.; Dejager, S.; Ahren, B.; Fonseca, V.; Ferrannini, E.; Couturier, A.; Foley, J. E.; Zinman, B.

研究方向